Fig. 8

3D-Exo ameliorated fibrosis through modulating TGFβRII/Smads signaling. a CLSM images of TGFβRII immunostaining in TGFβ-induced LX2 cells transfected with miR-6766-3p or its NC. Red: TGFβRII. Green: Tubulin. Blue: DAPI. (Original magnification, 20×, Scale bars, 40 μm) b The integrated optical density analysis of TGFβRII in a. c Western blot showed expression changes of TGFβRII fibrosis pathway-associated proteins were determined by Western blot in LX2 cells and activated LX2 cells after treatment with miR-6766-3p mimic or its NC. d The expressions of p-SMAD2, p-SMAD3 and SMAD4 in LX2 cells and activated LX2 with different treatments were detected by immunofluorescence analysis. Red: p-SMAD2/SMAD4. Green: p-SMAD2/SMAD4. Blue: DAPI. (Original magnification, 20×, Scale bars, 40 μm). e The integrated optical density analysis of p-SMAD2, p-SMAD3 and SMAD4 in d. f The gene expressions of SMAD2, SMAD3, SMAD4, P38 MAPK and ERK1 were verified by qPCR in LX2 cells and TGFβ-induced LX2 cells under the treatment with miR-6766-3p mimic or its NC. g The expressions of P38 MAPK and ERK1 were detected by immunofluorescence staining in LX2 cells and TGFβ-induced LX2 cells after the addition of miR-6766-3p mimic or its NC. h Quantification of integrated optical density of P38 MAPK and ERK1 in g. Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001